Antiphospholipid Antibody Syndrome and Infertility

Vivian de Oliveira Rodrigues; Adriana de Góes e Silva Soligo; Gabriel Duque Pannain

doi:10.1055/s-0039-1697982

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, Inhaltsverzeichnis

CC BY 4.0 · Rev Bras Ginecol Obstet 2019; 41(10): 621-627
DOI: 10.1055/s-0039-1697982

Review Article

Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Antiphospholipid Antibody Syndrome and Infertility

Síndrome Anticorpo Antifosfolípide e Infertilidade

Vivian de Oliveira Rodrigues

¹Gynecology Department, Faculdade de Medicina, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil

,

Adriana de Góes e Silva Soligo

²Post Graduate Department, Associação Instituto Sapientiae, São Paulo, SP, Brazil

,

Gabriel Duque Pannain

¹Gynecology Department, Faculdade de Medicina, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil

› Institutsangaben

Abstract

Antiphospholipid antibody syndrome (APS) is a systemic, autoimmune, prothrombotic disease characterized by persistent antiphospholipid antibodies (aPLs), thrombosis, recurrent abortion, complications during pregnancy, and occasionally thrombocytopenia. The objective of the present study was to review the pathophysiology of APS and its association with female infertility. A bibliographic review of articles of the past 20 years was performed at the PubMed, Scielo, and Bireme databases. Antiphospholipid antibody syndrome may be associated with primary infertility, interfering with endometrial decidualization and with decreased ovarian reserve. Antiphospholipid antibodies also have direct negative effects on placentation, when they bind to the trophoblast, reducing their capacity for invasion, and proinflammatory effects, such as complement activation and neutrophil recruitment, contributing to placental insufficiency, restricted intrauterine growth, and fetal loss. In relation to thrombosis, APS results in a diffuse thrombotic diathesis, with global and diffuse dysregulation of the homeostatic balance. Knowing the pathophysiology of APS, which is closely linked to female infertility, is essential for new therapeutic approaches, specialized in immunomodulation and inflammatory signaling pathways, to provide important advances in its treatment.

Resumo

A Síndrome do anticorpo antifosfolípide (SAF) é uma doença sistêmica, autoimune e pró-trombótica caracterizada por anticorpos antifosfolípides, trombose, aborto recorrente, complicações durante a gestação, e, ocasionalmente, trombocitopenia. O objetivo do presente estudo foi revisar a fisiopatologia da SAF e sua associação com a infertilidade feminina. Foi feita uma revisão bibliográfica dos últimos 20 anos nas bases de dados PubMed, Scielo e Bireme. A SAF pode estar associada à infertilidade primária, interferindo na decidualização endometrial e com baixas reservas ovarianas. Os anticorpos antifosfolípides também apresentam efeito negativo direto na placentação, se ligando ao trofoblasto e diminuindo sua capacidade de invasão, além de efeitos pró-inflamatórios, tais como ativação do sistema de complemento e recrutamento de neutrófilos, contribuindo para a insuficiência placentária, crescimento intrauterino restrito e perda fetal. Quanto a trombose, a SAF resulta em distúrbios trombóticos difusos, com uma desregulação do balanço homeostático. Conhecer a fisiopatologia da SAF, que apresenta associação importante com a infertilidade feminina, é essencial para novas abordagens terapêuticas, principalmente no que tange imunomodulação e os caminhos de ativação inflamatórios.

Keywords

antiphospholipid antibody syndrome - infertility - recurrent abortion - antiphospholipid antibody

Palavras-chave

síndrome do anticorpo antifosfolípide - infertilidade - aborto de repetição - anticorpo antifosfolípide

Volltext

Referenzen

References
1 D'Ippolito S, Meroni PL, Koike T, Veglia M, Scambia G, Di Simone N. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev 2014; 13 (09) 901-908 . Doi: 10.1016/j.autrev.2014.05.004
2 Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 2014; 48-49: 20-25 . Doi: 10.1016/j.jaut.2014.01.006
3 Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev 2017; 31 (06) 406-417 . Doi: 10.1016/j.blre.2017.07.006
4 Celli CM, Gharavi AE. Origin and pathogenesis of antiphospholipid antibodies. Braz J Med Biol Res 1998; 31 (06) 723-732 . Doi: 10.1590/s0100-879 × 1998000600002
5 Ruiz-García R, Serrano M, Martínez-Flores JA. , et al. Isolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J Immunol Res 2014; 2014: 704395 . Doi: 10.1155/2014/704395
6 Ulcova-Gallova Z. The role of antiphospholipid antibodies (aPls) in infertile women: the long-lasting experience. Reprod Med Biol 2014; 14 (02) 49-55 . Doi: 10.1007/s12522-014-0196-y
7 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306 . Doi: 10.1111/j.1538-7836.2006.01753.x
8 Deroux A, Dumestre-Perard C, Dunand-Faure C, Bouillet L, Hoffmann P. Female infertility and serum autoantibodies: a systematic review. Clin Rev Allergy Immunol 2017; 53 (01) 78-86 . Doi: 10.1007/s12016-016-8586-z
9 Kovács M, Hartwig M, Aleksza M. , et al. Antiphospholipid antibodies in relation to sterility/infertility. Hum Immunol 2012; 73 (07) 726-731 . Doi: 10.1016/j.humimm.2012.04.003
10 Chighizola CB, Raimondo MG, Meroni PL. Does APS impact women's fertility?. Curr Rheumatol Rep 2017; 19 (06) 33 . Doi: 10.1007/s11926-017-0663-7
11 Holers VM, Girardi G, Mo L. , et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195 (02) 211-220 . Doi: 10.1084/jem.200116116
12 Levine AB, Lockshin MD. Antiphospholipid syndrome. In: Sammaritano LR, Bermas BL. , eds. Contraception and Pregnancy in Patients with Rheumatic Disease. New York, NY: Springer; 2014: 109-137
13 Kutteh WH, Hinote CD. Antiphospholipid antibody syndrome. Obstet Gynecol Clin North Am 2014; 41 (01) 113-132 . Doi: 10.1016/j.ogc.2013.10.004
14 Chighizola CB, Pregnolato F, Raschi E. , et al. Antiphospholipid antibodies and infertility: a gene expression study in decidual stromal cells. Isr Med Assoc J 2016; 18 (3-4): 146-149
15 Chauleur C, Galanaud JP, Alonso S. , et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost 2010; 8 (04) 699-706 . Doi: 10.1111/j.1538-7836.2010.03747.x
16 Oron G, Ben-Haroush A, Goldfarb R, Molad Y, Hod M, Bar J. Contribution of the addition of anti-β2-glycoprotein to the classification of antiphospholipid syndrome in predicting adverse pregnancy outcome. J Matern Fetal Neonatal Med 2011; 24 (04) 606-609 . Doi: 10.3109/14767058.2010.511339
17 Cervera R, Piette JC, Font J. , et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46 (04) 1019-1027 . Doi: 10.1002/art.10187
18 Rai RS, Regan L, Clifford K. , et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10 (08) 2001-2005 . Doi: 10.1093/oxfordjournals.humrep.a136224
19 Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33 (11) 2214-2221
20 Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?. Curr Rheumatol Rep 2007; 9 (03) 219-225
21 do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol 2010; 116 (06) 1433-1443 . Doi: 10.1097/AOG.0b013e3181fe02ec
22 Schreiber K, Radin M, Sciascia S. Current insights in obstetric antiphospholipid syndrome. Curr Opin Obstet Gynecol 2017; 29 (06) 397-403 . Doi: 10.1097/GCO.0000000000000406
23 Pengo V, Ruffatti A, Legnani C. , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718 . Doi: 10.1182/blood-2011-03-340232
24 Di Simone N, Di Nicuolo F, D'Ippolito S. , et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010; 83 (02) 212-219 . Doi: 10.1095/biolreprod.110.083410
25 Gellersen B, Brosens JJ. Cyclic decidualization of the human endometrium in reproductive health and failure. Endocr Rev 2014; 35 (06) 851-905 . Doi: 10.1210/er.2014-1045
26 Branch DW, Dudley DJ, Mitchell MD. , et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163 (1 Pt 1): 210-216 . Doi: 10.1016/s0002-9378(11)90700-5
27 Chaouat G. Inflammation, NK cells and implantation: friend and foe (the good, the bad and the ugly?): replacing placental viviparity in an evolutionary perspective. J Reprod Immunol 2013; 97 (01) 2-13 . Doi: 10.1016/j.jri.2012.10.009
28 Girardi G, Berman J, Redecha P. , et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112 (11) 1644-1654 . Doi: 10.1172/JCI18817
29 Vega M, Barad DH, Yu Y. , et al. Anti-mullerian hormone levels decline with the presence of antiphospholipid antibodies. Am J Reprod Immunol 2016; 76 (04) 333-337 . Doi: 10.1111/aji.12551
30 Tal R, Seifer DB. Ovarian reserve testing: a user's guide. Am J Obstet Gynecol 2017; 217 (02) 129-140 . Doi: 10.1016/j.ajog.2017.02.027
31 Yamakami LY, Serafini PC, de Araujo DB. , et al. Ovarian reserve in women with primary antiphospholipid syndrome. Lupus 2014; 23 (09) 862-867 . Doi: 10.1177/0961203314529468
32 Chighizola CB, de Jesus GR, Branch DW. The hidden world of anti-phospholipid antibodies and female infertility: A literature appraisal. Autoimmun Rev 2016; 15 (06) 493-500 . Doi: 10.1016/j.autrev.2016.01.018
33 Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 2006; 27 (9-10): 939-958 . Doi: 10.1016/j.placenta.2005.12.006
34 Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009; 30 (06) 473-482 . Doi: 10.1016/j.placenta.2009.02.009
35 Abrahams VM, Chamley LW, Salmon JE. Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation. Arthritis Rheumatol 2017; 69 (09) 1710-1721 . Doi: 10.1002/art.40136
36 Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimmun Rev 2015; 14 (05) 446-471 . Doi: 10.1016/j.autrev.2015.01.008
37 Saccone G, Berghella V, Maruotti GM. , et al; PREGNANTS (PREGNancy in women with ANTiphospholipid Syndrome) working group. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol 2017; 216 (05) 525.e1-525.e12 . Doi: 10.1016/j.ajog.2017.01.026
38 Ulrich V, Gelber SE, Vukelic M. , et al. ApoE receptor 2 mediation of trophoblast dysfunction and pregnancy complications induced by antiphospholipid antibodies in mice. Arthritis Rheumatol 2016; 68 (03) 730-739 . Doi: 10.1002/art.39453
39 Huppertz B, Kingdom J, Caniggia I. , et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003; 24 (2-3): 181-190 . Doi: 10.1053/plac.2002.0903
40 Albrecht C, Soumian S, Tetlow N. , et al. Placental ABCA1 expression is reduced in primary antiphospholipid syndrome compared to pre-eclampsia and controls. Placenta 2007; 28 (07) 701-708 . Doi: 10.1016/j.placenta.2006.10.001
41 Marchetti T, Ruffatti A, Wuillemin C, de Moerloose P, Cohen M. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost 2014; 12 (06) 910-920 . Doi: 10.1111/jth.12570
42 Gelber SE, Brent E, Redecha P. , et al. Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency. J Immunol 2015; 195 (03) 1129-1138 . Doi: 10.4049/jimmunol.1402220
43 Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196 (02) 167.e1-167.e5
44 Huber-Lang M, Sarma JV, Zetoune FS. , et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12 (06) 682-687 . Doi: 10.1038/nm1419
45 Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1 (05) 931-942 . Doi: 10.1046/j.1538-7836.2003.00125.x
46 Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus 2008; 17 (05) 405-411 . Doi: 10.1177/0961203308090025
47 Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52 (07) 2120-2124 . Doi: 10.1002/art.21157